← All Alaunos Therapeutics, INC filings

Alaunos Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TCRT
Alaunos Therapeutics, INC
10-K/A: Alaunos Therapeutics Files 10-K/A for Governance Updates
Alaunos Therapeutics, Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding directors, executive compensation, and corporate governance.
NASDAQ
TCRT
Alaunos Therapeutics, INC
10-K: Alaunos Therapeutics Shifts to Obesity Focus Amid Financial Strain
Alaunos Therapeutics reports positive preclinical data for its obesity program ALN1003 but faces substantial doubt about its ability to continue as a going concern and Nasdaq delisting risk.
NASDAQ
TCRT
Alaunos Therapeutics, INC
10-K/A: Alaunos Therapeutics Files Amendment No. 1 to Form 10-K, Providing Additional Corporate Governance and Executive Compensation Details
Alaunos Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include information on directors, executive officers, corporate governance, and executive compensation.
NASDAQ
TCRT
Alaunos Therapeutics, INC
10-K: Alaunos Therapeutics Shifts Focus to Obesity Drug Development Amid Strategic Review
Alaunos Therapeutics pivots to preclinical obesity drug development while exploring strategic alternatives after halting TCR-T clinical programs.
NASDAQ
TCRT
Alaunos Therapeutics, INC
10-K: Alaunos Therapeutics Halts Clinical Programs, Explores Strategic Alternatives Amidst Financial Constraints
Alaunos Therapeutics has ceased development of its clinical programs and reduced its workforce by 95% as it explores strategic alternatives due to substantial costs and a challenging financing environment.